Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson
Dr. Alex Marson (guest), Andrew Huberman (host)
In this episode of Huberman Lab, featuring Dr. Alex Marson and Andrew Huberman, Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson explores reprogramming immunity with CRISPR and CAR T to fight cancer Dr. Alex Marson explains the immune system’s core logic—distinguishing self from non-self—by contrasting innate “alarm” responses with adaptive B- and T-cell specificity shaped by thymic selection.
Reprogramming immunity with CRISPR and CAR T to fight cancer
Dr. Alex Marson explains the immune system’s core logic—distinguishing self from non-self—by contrasting innate “alarm” responses with adaptive B- and T-cell specificity shaped by thymic selection.
They frame cancer as an evolutionary genetic process: mutations accumulate over time, occasionally producing cells that evade normal control and proliferate, with risks amplified by mutagens (e.g., smoking, UV) and certain inherited predispositions (e.g., BRCA).
The episode details the modern shift from chemo-only paradigms to immune-based cancer treatments, including checkpoint inhibitors and engineered CAR T cells, and shows how CRISPR enables more precise, programmable cell therapies.
They also address delivery technologies (electroporation, engineered viruses, lipid nanoparticles), emerging AI-designed binding proteins, and ethical boundaries—especially opposition to heritable embryo editing and skepticism about “perfection” selection via deep embryo sequencing.
Key Takeaways
Adaptive immunity is built on probabilistic diversity plus selection.
T and B cells generate highly diverse receptors largely at random; the thymus then positively/negatively selects T cells to reduce self-reactivity, though some self-reactive cells still escape and must be controlled by secondary mechanisms.
Get the full analysis with uListen AI
Autoimmunity reflects imperfect immune “quality control,” not a single failure mode.
Self-reactive cells can slip through selection; disease occurs when tolerance checkpoints fail in specific tissues (joints, pancreas, myelin), motivating therapies that suppress only the harmful responses rather than blanket immunosuppression.
Get the full analysis with uListen AI
Systemic sickness symptoms often come from immune signaling, not just the pathogen.
Cytokines released locally can circulate and trigger body-wide effects such as fever and malaise; sometimes the immune response overshoots and contributes substantially to how sick you feel.
Get the full analysis with uListen AI
Cancer risk increases with age mainly because time allows mutation accumulation and selection.
Every cell division risks replication errors; most damaged cells die, but occasionally mutations confer a growth advantage, enabling clonal expansion and further “hits” that can culminate in cancer.
Get the full analysis with uListen AI
Big, high-confidence cancer risks are known; many smaller ones remain hard to quantify.
Smoking and excessive UV exposure are highlighted as major mutagenic drivers; other exposures (pesticides, charred meats, low-dose radiation like scanners/X-rays, additives) likely contribute variably, but dose/real-world risk is often uncertain.
Get the full analysis with uListen AI
Immunotherapy changed cancer care by leveraging the body’s existing surveillance system.
Checkpoint inhibitors (e. ...
Get the full analysis with uListen AI
CAR T cells work best when the target is ‘dispensable’ on healthy tissue.
Early CAR T success (CD19) works partly because losing normal B cells is tolerable; extending CAR T to solid tumors is harder because many targets are shared with essential healthy tissues, driving interest in multi-signal (“two-factor”) recognition.
Get the full analysis with uListen AI
CRISPR’s real power is programmability and scale, not just editing.
A guide RNA directs Cas enzymes to specific DNA sites, enabling targeted cuts or edits; modern approaches include high-fidelity variants, base editors, and epigenetic editing to reduce risks from double-strand breaks and unintended consequences.
Get the full analysis with uListen AI
Delivery is the bottleneck—and it’s improving rapidly.
Marson’s lab helped pioneer electroporation of CRISPR protein/RNA into primary human T cells; newer approaches include engineered viral tropism, virus-like particles, and lipid nanoparticles that can target cell types (with liver as a current strength and T-cell targeting emerging).
Get the full analysis with uListen AI
The ethical bright line (for Marson) is heritable genome editing.
He supports somatic editing for treatment but argues against embryo edits that pass to future generations, citing unpredictable long-term effects, loss of diversity, and social harms from “designed” offspring—also expressing skepticism about algorithmic embryo ‘desirability’ scoring.
Get the full analysis with uListen AI
Notable Quotes
“We can actually talk to our own cells and give them instructions in the language of DNA.”
— Dr. Alex Marson
“Each T cell will make its own receptor that is generated largely at random.”
— Dr. Alex Marson
“Cancer is… an evolutionary process where those cancerous cells have acquired new genetics that are focused on their well-being.”
— Dr. Alex Marson
“The dogma was, ‘Don’t waste time thinking about cancer immunology…’ …We were just wrong.”
— Dr. Alex Marson
“I think we should have a line in the sand where we do not introduce genetic edits that will be passed on to the next generation.”
— Dr. Alex Marson
Questions Answered in This Episode
On immune robustness: What measurable biomarkers (cell types, receptor diversity, cytokine responses) best predict who ‘gets sick often’ vs rarely?
Dr. ...
Get the full analysis with uListen AI
On thymus aging: How much does thymic involution contribute to immunosenescence, and are there credible interventions to preserve or restore thymic function?
They frame cancer as an evolutionary genetic process: mutations accumulate over time, occasionally producing cells that evade normal control and proliferate, with risks amplified by mutagens (e. ...
Get the full analysis with uListen AI
On lifestyle variables: What are the strongest mechanistic data linking sleep, obesity/metabolic health, and diet composition to specific changes in T-cell function in humans (not mice)?
The episode details the modern shift from chemo-only paradigms to immune-based cancer treatments, including checkpoint inhibitors and engineered CAR T cells, and shows how CRISPR enables more precise, programmable cell therapies.
Get the full analysis with uListen AI
On exposures: How should listeners reason about low-dose risks (airport scanners, dental X-rays, food dyes) when data are mostly high-dose animal studies—what framework would you use to estimate personal risk?
They also address delivery technologies (electroporation, engineered viruses, lipid nanoparticles), emerging AI-designed binding proteins, and ethical boundaries—especially opposition to heritable embryo editing and skepticism about “perfection” selection via deep embryo sequencing.
Get the full analysis with uListen AI
On charred meat: What specific mutagens form during charring (e.g., HCAs/PAHs), and is risk meaningfully reduced by cooking methods or marinades?
Get the full analysis with uListen AI
Transcript Preview
We're living in this amazing moment of biology where we can put a gene that encodes something on the surface of T cells that will make them programmed to search and destroy for cancer cells.
Mm-hmm.
Now, this is largely known as CAR T cells, chimeric antigen receptor. This is a receptor that was designed in a lab, does not exist in nature. When those T cells get reinfused into a patient the way that you get, like, a, a blood transfusion, those CARs are directed to go against cancers.
Welcome to the Huberman Lab Podcast, where we discuss science and science-based tools for everyday life. [guitar music] I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. My guest today is Dr. Alex Marson. Dr. Alex Marson is a medical doctor and scientist at the University of California San Francisco. He is developing new ways to reprogram the immune system to cure cancers. Today, we discuss how your immune system works, how autoimmunity works, and how gene editing and other new technologies can be successfully leveraged to defeat childhood and adult cancers. Dr. Marson is truly one of a kind in his understanding of the clinical aspects of cancer treatment, the science of the immune system, and, as you'll soon hear, in explaining the things that genuinely increase your cancer risk, many of which are surprising, and the actionable steps that we can all take to reduce our probability of getting cancer. In addition to the usual factors, smoking, UV light, and environmental toxins such as pesticides, we discuss the actual cancer risks that come from things like eating charred meats, airport scanners, and food additives, and how to gauge your individual level of risk. We also explore gene editing for reversing diseases, which until recently was science fiction, but now is a reality. By the end of today's episode, thanks to Dr. Marson, you'll have the most up-to-date understanding of the state-of-the-art science for cancer prevention and treatment, knowledge that is certain to impact you or a close friend or family member in your lifetime. Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford. It is, however, part of my desire and effort to bring zero cost to consumer information about science and science-related tools to the general public. In keeping with that theme, today's episode does include sponsors. And now for my discussion with Dr. Alex Marson. Dr. Alex Marson, welcome.
Andrew.
This is the first time that we're going to have a serious discussion about the immune system, cancer, and gene editing technologies on this podcast, so I'm delighted that you're here. It's also great to see you again.
Thank you for having me. Really, really good to see you.
Yeah, it's been a while. Let's start off with the big picture.
Yeah.
Uh, how are we doing? How's, uh, how's biology looking? How's medicine looking? Are we, uh, are we on the fast track to much better things? Are we gonna slog along for another 10 years before we have cures to the many concerns that people have about cancer, Alzheimer's, and the rest? Or are you encouraged by what's happening right now?
Install uListen to search the full transcript and get AI-powered insights
Get Full TranscriptGet more from every podcast
AI summaries, searchable transcripts, and fact-checking. Free forever.
Add to Chrome